We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+17.71%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
+$505M
Cap. Flow
+$511M
Cap. Flow %
42.95%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$402M
2
NRIX icon
Nurix Therapeutics
NRIX
+$137M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.3B
$449M 37.75%
+10,551,115
New +$402M
RVMD icon
2
Revolution Medicines
RVMD
$42.1B
$279M 23.46%
8,024,031
-1,000,000
-11% -$27.7M
NRIX icon
3
Nurix Therapeutics
NRIX
$2.62B
$189M 15.9%
+5,422,549
New +$137M
PLRX icon
4
Pliant Therapeutics
PLRX
$65M
$132M 11.11%
5,839,160
– –
VYGR icon
5
Voyager Therapeutics
VYGR
$189M
$68.2M 5.73%
6,391,176
– –
FULC icon
6
Fulcrum Therapeutics
FULC
$288M
$47.3M 3.97%
5,962,202
– –
JNCE
7
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$24.9M 2.09%
3,048,780
– –

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q3 2020 Portfolio in Review

As of Q3 2020, TRV GP III held 7 positions worth $1.19B, up 74% from $685M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III deployed $511M of net new capital in Q3 2020, opening 2 new positions. Its largest new stake was Relay Therapeutics: 10,551,115 shares worth $449M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $27.7M trimmed.

  • TRV GP III's largest Q3 2020 buy was Relay Therapeutics: 10,551,115 shares worth $449M.
  • TRV GP III's biggest Q3 2020 reduction was Revolution Medicines, cutting an estimated $27.7M.
  • TRV GP III's ten largest holdings make up 100% of its $1.19B portfolio in Q3 2020.
  • TRV GP III opened 2 new positions and closed 0 in Q3 2020.
  • TRV GP III's portfolio value rose 74% quarter-over-quarter to $1.19B.

Based on TRV GP III's 13F filing for Q3 2020, filed 6 Nov 2020.